{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neonatal+Respiratory+Distress+Syndrome&page=11",
    "query": {
      "condition": "Neonatal Respiratory Distress Syndrome",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 418,
    "total_pages": 42,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neonatal+Respiratory+Distress+Syndrome&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Neonatal+Respiratory+Distress+Syndrome&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T22:45:19.445Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04843761",
      "title": "ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "Remdesivir",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Remdesivir Placebo",
          "type": "DRUG"
        },
        {
          "name": "Aviptadil",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Aviptadil Placebo",
          "type": "DRUG"
        },
        {
          "name": "Corticosteroid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 473,
      "start_date": "2021-04-20",
      "completion_date": "2022-11-20",
      "has_results": true,
      "last_update_posted_date": "2025-10-24",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 40,
      "location_summary": "Tucson, Arizona • Fresno, California • Loma Linda, California + 28 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04843761"
    },
    {
      "nct_id": "NCT04708340",
      "title": "Tolerability and Efficacy of RJX in Patients With COVID-19",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID-19",
        "Acute Respiratory Distress Syndrome",
        "SARS-CoV-2",
        "Hypoxemia"
      ],
      "interventions": [
        {
          "name": "Rejuveinix (RJX) Active Comparator",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Reven Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 237,
      "start_date": "2021-03-25",
      "completion_date": "2023-02",
      "has_results": false,
      "last_update_posted_date": "2022-03-15",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 3,
      "location_summary": "Houston, Texas • New Braunfels, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "New Braunfels",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04708340"
    },
    {
      "nct_id": "NCT00233207",
      "title": "IC14 Antibodies to Treat Individuals With Acute Lung Injury",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Distress Syndrome, Adult",
        "Lung Diseases"
      ],
      "interventions": [
        {
          "name": "IC14",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 13,
      "start_date": "2005-09",
      "completion_date": "2007-06",
      "has_results": false,
      "last_update_posted_date": "2017-05-16",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00233207"
    },
    {
      "nct_id": "NCT02636868",
      "title": "The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Lucinactant delivered via investigational delivery device",
          "type": "DRUG"
        },
        {
          "name": "nCPAP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Windtree Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "26 Weeks",
        "maximum_age": "32 Weeks",
        "sex": "ALL",
        "summary": "26 Weeks to 32 Weeks"
      },
      "enrollment_count": 221,
      "start_date": "2015-12",
      "completion_date": "2019-08-06",
      "has_results": true,
      "last_update_posted_date": "2021-04-23",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 22,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 18 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02636868"
    },
    {
      "nct_id": "NCT04388826",
      "title": "COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Distress Syndrome, Adult"
      ],
      "interventions": [
        {
          "name": "Veru-111",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Veru Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2020-06-18",
      "completion_date": "2021-08-13",
      "has_results": true,
      "last_update_posted_date": "2022-10-27",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Saint Louis Park, Minnesota • Saint Paul, Minnesota + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Saint Louis Park",
          "state": "Minnesota"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        },
        {
          "city": "Vineland",
          "state": "New Jersey"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04388826"
    },
    {
      "nct_id": "NCT04412668",
      "title": "Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "SARS-CoV-2 (COVID-19) Severe Pneumonia"
      ],
      "interventions": [
        {
          "name": "Efzofitimod 1 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Efzofitimod 3 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "aTyr Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 36,
      "start_date": "2020-06-04",
      "completion_date": "2020-10-23",
      "has_results": true,
      "last_update_posted_date": "2023-08-18",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 5 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Annapolis",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04412668"
    },
    {
      "nct_id": "NCT03038906",
      "title": "Effect of Randomization to Neuromuscular Blockade on Physical Functional Impairment and Recovery in ARDS",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Respiratory Distress Syndrome",
        "Neuromyopathies"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 290,
      "start_date": "2017-01",
      "completion_date": "2020-09",
      "has_results": false,
      "last_update_posted_date": "2017-02-01",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03038906"
    },
    {
      "nct_id": "NCT00142376",
      "title": "Short Term Outcomes of Children With Acute Respiratory Distress Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Nationwide Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "0 Years to 18 Years"
      },
      "enrollment_count": null,
      "start_date": "2004-09",
      "completion_date": "2005-08",
      "has_results": false,
      "last_update_posted_date": "2005-09-02",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00142376"
    },
    {
      "nct_id": "NCT04402060",
      "title": "A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "COVID",
        "Covid-19",
        "Coronavirus",
        "Coronavirus Infection",
        "Severe Acute Respiratory Syndrome",
        "Severe Acute Respiratory Syndrome Coronavirus 2",
        "Sars-CoV2",
        "Ards",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "APL-9",
          "type": "DRUG"
        },
        {
          "name": "Vehicle Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Apellis Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2020-05-28",
      "completion_date": "2021-02-13",
      "has_results": true,
      "last_update_posted_date": "2022-03-23",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 16,
      "location_summary": "Fresno, California • San Francisco, California • Jacksonville Beach, Florida + 12 more",
      "locations": [
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Jacksonville Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04402060"
    },
    {
      "nct_id": "NCT00351533",
      "title": "A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Respiratory Distress Syndrome, Adult",
        "Acute Lung Injury",
        "Acute Respiratory Distress Syndrome"
      ],
      "interventions": [
        {
          "name": "Fish oil (eicosapentaenoic acid and docosahexanoic acid)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2006-07",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2011-10-03",
      "last_synced_at": "2026-10-21T22:45:19.445Z",
      "location_count": 4,
      "location_summary": "Boise, Idaho • Portland, Oregon • Burlington, Vermont + 1 more",
      "locations": [
        {
          "city": "Boise",
          "state": "Idaho"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Burlington",
          "state": "Vermont"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00351533"
    }
  ]
}